Cart
sales@molnova.com
N-(2,6-dioxopiperidin-3-yl)-4-nitrophthalimide
CAS No. 55003-81-1
N-(2,6-dioxopiperidin-3-yl)-4-nitrophthalimide( 2-(2,6-dioxopiperidin-3-yl)-5-nitroisoindoline-1,3-dione )
Catalog No. M28630 CAS No. 55003-81-1
N-(2,6-dioxopiperidin-3-yl)-4-nitrophthalimide exhibit inhibition of CRBN.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 50MG | 27 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameN-(2,6-dioxopiperidin-3-yl)-4-nitrophthalimide
-
NoteResearch use only, not for human use.
-
Brief DescriptionN-(2,6-dioxopiperidin-3-yl)-4-nitrophthalimide exhibit inhibition of CRBN.
-
DescriptionN-(2,6-dioxopiperidin-3-yl)-4-nitrophthalimide exhibit inhibition of CRBN.
-
In Vitro——
-
In Vivo——
-
Synonyms2-(2,6-dioxopiperidin-3-yl)-5-nitroisoindoline-1,3-dione
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number55003-81-1
-
Formula Weight303.23
-
Molecular FormulaC13H9N3O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[O-][N+](c(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Howard I, et al. An expeditious route to the synthesis of kelampayosides A and B. Tetrahedron Lett. 1999;55(32): 9881-9898.
molnova catalog
related products
-
N-Acetyl-L-aspartic ...
N-Acetylaspartic acid is a derivative of aspartic acid. It is the second most concentrated molecule in the brain after the amino acid glutamate. It is synthesized in neurons from the amino acid aspartate and acetyl coenzyme A (acetyl CoA).
-
3-phenoxy-8-azabicyc...
3-phenoxy-8-azabicyclo[3.2.1]octane hydrochloride is a chemical compound.
-
Lirilumab
Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition.
